Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Envafolimab with Neoadjuvant Chemotherapy in Stage IIb Osteosarcoma
NCT07142863Phase 2Not yet recruiting
- Sponsor
- Shanghai General Hospital
- Start
- Aug 2025
- Primary completion
- Aug 2026
- Modality
- Nanobodies (VHH), Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of envafolimab in osteosarcoma (OS), sponsored by Shanghai General Hospital. Planned start Aug 2025; status: not yet recruiting.
02
Drugs
envafolimab
03
Conditions
osteosarcoma (OS)
Beyond the preview
Go deeper on NCT07142863.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07142863.